TY  - CHAP
M1  - Book, Section
TI  - Chapter 25. Perspective on Gastrointestinal Stromal Tumors
A1  - DeMatteo, Ronald P.
A2  - Zinner, Michael J.
A2  - Ashley, Stanley W.
PY  - 2013
T2  - Maingot's Abdominal Operations, 12e
AB  - In  the  accompanying  chapter,  Dr  Raut  provides  an  overview  of  gastrointestinal  stromal  tumor  (GIST).  Clearly,  the  development  of  tyrosine  kinase  inhibitors  for  GIST  is  one  of  the  most  remarkable  achievements  to  date  for  any  solid  tumor.  Patients  with  metastatic  GIST  historically  had  a  median  survival  of  12  months,  but  it  is  now  5  years.1,2  The  paradigm  of  targeted  molecular  therapy  has  been  subsequently  expanded  to  lung  adenocarcinoma  with  epidermal  growth  factor  receptor  (EGFR)  inhibitors,  renal  carcinoma  with  vascular  endothelial  growth  factor  receptor  (VEGFR)  inhibitors,  and  most  recently  melanoma  with  B-Raf  inhibitors.  Although  GIST  is  an  uncommon  tumor,  lessons  from  “the  GIST  story”  will  have  relevance  to  the  multimodality  therapy  of  these  more  common  tumors  and  other  cancers  for  which  targeted  therapy  is  developed.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesssurgery.mhmedical.com/content.aspx?aid=57011857
ER  -